Monday, September 07, 2020 10:09:05 PM
Galera's Phase 3 (335 participants), started in October 2018, has an Estimated Primary Completion Date of October 2020. When do you think IPIX will have their P3 Actual Study Start Date?
ps. Thanks for the link...I don't have any articles handy.
I'm not questioning the truth of what the Company is saying. I just don't understand it. Quit whining and explain it.
Recent GRTX News
- Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updates • GlobeNewswire Inc. • 03/28/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 09:06:04 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 02/20/2024 11:57:58 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 01/16/2024 11:11:39 PM
- Galera Reports Third Quarter 2023 Financial Results and Recent Corporate Updates • GlobeNewswire Inc. • 11/14/2023 12:00:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 11/13/2023 07:24:56 PM
- Galera Shares Halted After FDA Says Avasopasem Needs Additional Phase 3 Trial • Dow Jones News • 10/31/2023 12:09:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2023 11:10:53 AM
- Galera Announces Receipt of Type A Meeting Minutes and Strategic Update • GlobeNewswire Inc. • 10/31/2023 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/26/2023 11:24:59 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/22/2023 09:12:53 PM
- Galera Schedules Type A Meeting with FDA to Discuss Next Steps for Avasopasem • GlobeNewswire Inc. • 09/18/2023 11:00:00 AM
- Galera to Participate in the H.C. Wainwright 25th Annual Global Investment Conference • GlobeNewswire Inc. • 09/05/2023 11:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 11:30:36 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2023 11:10:28 AM
- Galera Reports Second Quarter 2023 Financial Results and Recent Corporate Updates • GlobeNewswire Inc. • 08/14/2023 11:00:17 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/10/2023 12:00:58 PM
- Stocks to Watch: Applovin, Disney, Galera Therapeutics • Dow Jones News • 08/10/2023 12:10:00 AM
- Galera Therapeutics to Reduce Workforce by 70% to Extend Cash Runway • Dow Jones News • 08/09/2023 09:23:00 PM
- Galera Receives Complete Response Letter from U.S. FDA for Avasopasem Manganese • GlobeNewswire Inc. • 08/09/2023 08:31:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/05/2023 08:11:02 PM
- Galera Presents Additional Chronic Kidney Disease Data from ROMAN Trial at 2023 ASCO Annual Meeting • GlobeNewswire Inc. • 06/05/2023 06:15:00 PM
- Galera Therapeutics Gets Orphan Drug Designation for Rucosopasem • Dow Jones News • 05/18/2023 12:44:00 PM
- Galera Announces FDA Orphan Drug Designation Granted to Rucosopasem for Pancreatic Cancer • GlobeNewswire Inc. • 05/18/2023 12:00:00 PM
- Galera Reports First Quarter 2023 Financial Results and Recent Corporate Updates • GlobeNewswire Inc. • 05/11/2023 11:00:00 AM
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors • EDXC • Mar 27, 2024 3:01 PM
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules • AUVI • Mar 27, 2024 2:51 PM
POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks • POET • Mar 27, 2024 10:52 AM
Maybacks Global Entertainment Opens 23 More Stations in Important Major Cities • AHRO • Mar 27, 2024 9:00 AM
NxGen Brands Inc. Forecast to Deliver 140% Growth in Q1 2024 • NXGB • Mar 27, 2024 7:30 AM
Kona Gold Beverages, Inc. Strategic Advancements: Covert LLC Introduces Federally Legal D9 Gummies and Revamps Innovative eCommerce Platform, Propelling Toward $12 Million Annual Revenue Goal • KGKG • Mar 26, 2024 8:30 AM